Skip to main content

Table 2 COX model analysis based on METTL3 expression and patients’ clinical parameters

From: The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma

Variables

HR (95% CI)

P

HR (95% CI)

P

Gender (male: female)

0.929 (0.451 ~ 1.914)

0.842

1.723 (0.763 ~ 3.888)

0.190

Age (> 60: ≤ 60 years)

3.117 (1.465 ~ 6.634)

0.003

5.652 (2.348 ~ 13.609)

0.000

Pathological stage (III + IV: I + II)

5.028 (2.423 ~ 10.435)

0.000

5.799 (2.389 ~ 14.075)

0.000

Tumor size (≥ 5: < 5 cm)

1.732 (0.829 ~ 3.618)

0.144

0.991 (0.373 ~ 2.639)

0.986

Tumor position (right: left)

0.950 (0.469 ~ 1.921)

0.885

0.809 (0.366 ~ 1.790)

0.601

T stage (II + III: I)

3.544 (1.731 ~ 7.259)

0.001

3.849 (1.530 ~ 9.688)

0.004

Distance metastasis (M1: M0)

8.882 (1.954 ~ 40.372)

0.005

3.745 (0.367 ~ 38.232)

0.265

TNM stage (III + IV: I + II)

3.433 (1.193 ~ 9.879)

0.022

1.239 (0.256 ~ 5.986)

0.790

METTL3 expression (high: low)

2.379 (1.221 ~ 5.258)

0.013

4.071 (1.624 ~ 10.208)

0.003

  1. Bold signifies P < 0.05